ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Novavax taps Japan's AGC to make ingredient in COVID-19 shot

Manufacturer produces compound for boosting vaccine candidate's effectiveness

Novavax's COVID-19 candidate vaccine is administered to a clinical trial participant in Australia in this Australian Broadcasting Corp. image. (Photo courtesy of Novavax)

TOKYO -- Chemical and materials group AGC has started producing an additive for a coronavirus vaccine candidate being developed by U.S. company Novavax, the Japanese manufacturer said Thursday.

U.S. subsidiary AGC Biologics has been contracted to produce an adjuvant, a compound that improves a vaccine's effectiveness. The agent is being manufactured at a plant in Denmark.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more